No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

11 trials linked to this intervention

Total Trials

Recruiting

With Results

Recent Trials

Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation

NCT00336531Phase 4Completed100 enrolled

Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms

NCT01005654Recruiting2415 enrolled

Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies

NCT01109394Recruiting6035 enrolled

Pediatric Precision Laboratory Advanced Neuroblastoma Therapy

NCT02559778Phase 2Recruiting500 enrolled

Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)

NCT03213652Phase 2Active Not Recruiting13 enrolled

View all 11 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:

Outcomes of fludarabine-melphalan versus fludarabine-busulfan reduced-intensity conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies: A systematic review and meta-analysis.

Wannaphut Chalothorn, Chumnumsiriwath Piyatida, Ciurea Stefan O et al. · Cancer · 2025

PMID: 41351867Meta-Analysis

A systematic review of inter-individual differences in the DNA repair processes involved in melphalan monoadduct repair in relation to treatment outcomes.

van Kan Maia, Burns Kathryn E, Helsby Nuala A · Cancer Chemother Pharmacol · 2021

PMID: 34347127Meta-Analysis

The effects of different schedules of bortezomib, melphalan, and prednisone for patients with newly diagnosed multiple myeloma who are transplant ineligible: a matching-adjusted indirect comparison.

Mateos Maria-Victoria, San-Miguel Jesus, Goldschmidt Hartmut et al. · Leuk Lymphoma · 2020

PMID: 31686561Meta-Analysis

Choosing a Reduced-Intensity Conditioning Regimen for Allogeneic Stem Cell Transplantation, Fludarabine/Busulfan versus Fludarabine Melphalan: A Systematic Review and Meta-Analysis.

Jain Tania, Alahdab Fares, Firwana Belal et al. · Biol Blood Marrow Transplant · 2019

PMID: 30471339Meta-Analysis

Isolated limb infusion with melphalan and actinomycin D for melanoma: a systematic review.

Kroon Hidde M, Huismans Anna M, Kam Peter C A et al. · J Surg Oncol · 2014

PMID: 24522939Meta-Analysis

Isolated limb perfusion with melphalan in the treatment of malignant melanoma of the extremities: a systematic review of randomised controlled trials.

Lens Marko B, Dawes Martin · Lancet Oncol · 2003

PMID: 12788409Meta-Analysis

Induction therapy with bortezomib, melphalan, and prednisone followed by lenalidomide and dexamethasone versus carfilzomib, lenalidomide, and dexamethasone with or without daratumumab in older, fit patients with newly diagnosed multiple myeloma (GEM-2017FIT): a phase 3, open-label, multicentre, randomised clinical trial.

Mateos María-Victoria, Paiva Bruno, Cedena M Teresa et al. · Lancet Haematol · 2025

PMID: 40769684RCT

An Open-label, Randomized Study of Melphalan/Hepatic Delivery System Versus Best Alternative Care in Patients with Unresectable Metastatic Uveal Melanoma.

Zager Jonathan S, Orloff Marlana, Ferrucci Pier Francesco et al. · Ann Surg Oncol · 2025

PMID: 40192993RCTFull text (PMC)

Impact of age on safety of Busulfan-Melphalan followed by autologous hematopoietic stem-cell transplantation versus standard chemotherapy in the patients of the EURO-E.W.I.N.G. 99 and Ewing 2008 clinical trials.

Choderlos de Laclos Xavier, Risbourg Séverine, Brennan Bernadette et al. · Eur J Cancer · 2024

PMID: 39032218RCTFull text (PMC)

Clinical and safety outcomes of BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) versus CEM (Carboplatin, Etoposide, Melphalan) in lymphoma patients as a conditioning regimen before autologous hematopoietic cell transplantation.

Eltelbanei Mohamed A, El-Bassiouny Noha A, Abdalla Mahmoud Salah et al. · BMC Cancer · 2024

PMID: 39134959RCTFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type: Substance / Medication
Fully Specified Name: Melphalan (substance)
SNOMED CT: 387297002
UMLS CUI: C0025241
RxNorm CUI: 6718

Clinical Data

This intervention maps to 5 entities in the Healos knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.